Time course of moricizine's effect on signal-averaged and 12 lead electrocardiograms: Insights into mechanism of action  by Wechsler, Mindy E. et al.
REPORTS ON THERAPY 
Time Course of Moricizine’s Effect on Signal-Averaged and 12 Lead 
Electrocardiograms: Insights Into Mechanism of Action 
MINDY E. WECHSLER. BS. JONATHAN S. STEINBERG. MD, FACC. 
ELSA-GRACE V. GIARDINA, MD, FACC 
Nm York. Nm York 
The mechanism of action of moricirine, a new antiarrhythmic 
agent used in the Cardiac Arrhythmia Supprewion Tvi& is 
incomplelely characterized. In addition, because moricizino is 
exlcnsively metabolized, plasma moricizbte concentration has au 
unknown relation to myorardial dru8 effect. Signalaveraged and 
standard etertroeardiogramr tECG#) we= wed to monttor mori. 
&in& mwcardiat c&ccLI in 16 natients with freaurnt VPntrieUlav 
premature eompl~xas taking 600 to 900 mg daily. Three signal- 
averaged ECG varishles were measured: total filtered QRS dura- 
tiou ItQRS), xmtaueatwquare vollagc in the terminal 40 ms of 
ihr QRS cumpiex 6’40) and the terminal tow amplitude duration 
~40 pV (LA?.). At steady state, plasma sampI& were collected 
and serial recordings Srignalaveraged and standard ECGr were 
taken st 0, 1, 2, 4, 6 and 8 h after moricizine administration. A 
24 h amhulatary ECG war recorded throughout the test period. 
Maricidns prolonged lhc tQRS (p < 0.05) and decreased the 
“40 It, < 0.05, ol tie signat.avoraged KC and ,,rolonged “w 
Moricizine. the sole antiarrhythmic drug remaining in the 
Cardiac Arrhythmia Suppression Trial (CAST). is a well 
tolerated and effective new antiarrhythmic agent (l-8). 
Recently. moricirine WBE approved by the U.S. Food and 
Drug Administration for treatment of malignant ventricular 
arrhythmias. As the use of moricizine becomes more com- 
mon. it will be clinically useful to know if there is a relation 
between its cardiac effects and dose or concentration. Cur. 
renlly this infomrdion is limited by at least two consider- 
ations. First. the clinical effects of moricizine on cardiac 
conduction and repolarization are not clear. Because mori- 
cizine slows cardiac conduction, it has been classified as u 
-- 
QRS ,p < 0.05) and eorrcctrd JT IJTc) intervals ,p < 0.05) afthe 
standard ECG. The time course of the slgnelaveraged and 
standard ECG variables paralleled plasma moricizino roncentra. 
lion: lbat is, tbe maximal changes orcurved at 1 to 2 h and 
declined to time0 values st 8 h. The maximal change were: iQRS 
,+8%), V40 ,-33%J, QRS ,+S%) and JTc ,+4%b). Thus, 
dynamic changes were obwved tar intvaventricula~ conductian 
,fpRS, QRSI and ventrtculsr repalarization (JTc) over the dodng 
interval. 
In a subset of seven patients with r6 ventricular premature 
camplexes!h at steady slate on muriciaine, the frequency of 
ventricular premature cumpkxe~r related inversely with ptasma 
morieizins cancentratlon and changes on the signalwrragcd and 
standard RCGr. Noninvasive evaluation af moricizbie pmvided 
insight into the relation between drug concentratton and mywar- 
dial effect. 
(J Am CO,, C,,,&f1991;17:1626-33) 
typ I agent: however, it has also been subclassified as a 
classlA,9.l0~,aclass1Bo.andaclassICdrug,l3,l4). 
Lack of agreement about its classification suggests conflict 
regarding mortcizinc’s clinical etectrophysiologic effects. 
While there are limitations in attempting to classify antiar- 
rhythmic agents. one benefit of such organization is that it 
allows conduction and repolarization effects to be readily 
described. Second. because moricizine is extensively metab- 
olized it has been suggested that no significant relation exists 
between drug concentration and m:‘ocardial effects- 
particularly those on the electrocardiogram (EC@. For 
other antiarrbytbmic drugs such as procainamide (15) or 
flecainide (16) and even drugs that undergo extensive metab- 
olism. such as encainide (17). the relation between concen- 
tration and ECG changes has been useful in guiding therapy. 
Previously. the signal-averaged EC% has not been used for 
this purpose. but it offers the potential advantage ofgreater 
sensitivity to QRS duration (18.19) and, moreover, can 
detect changes in the activation of segments late in the 
ventricular depolarization sequence (late potentials) that 
may represent slow conducting myocardial tissue. a sub- 
strate for reenfrsnl arrhythmias (20-22). 
In the present study, the electrocardiographic effects of 
moricizine were assessed noninvarively with the signal- 
averaged and the standard ECGs in patients with frequent 
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ventricular premature complcncs. The Wdy-5 ob~ecrmes 
were I) to evaluate moricizioe’s effect on sianal-avcraacd 
ECG variables and slandard ECC intervals. ?i,o deter&e 
the time course of moricizine concentration in plasma over 
an 8 h dosing interval. and 3) to explore the relation betueen 
suppression of ventricular premarure complexes and mu+ 
cizine’s effect on conduction and repolar~za,mn. 
Methods 
Study design. Patients who participated in the study had 
230 ventricular premature complexes/h on two ~onse~~ti~e 
24 h ambulatory (Halter) KG recordings during a basebne 
placebo period and were panicipating in a xrudy of optimal 
dosing (two YE. three times daily) of moriciLine for suppres- 
sion of ventricular oremature comolexe~. Patients ewe 
written iniomted consent to participate. The institutional 
Review Board of Columbia-Presbvterian Medical Center 
approved the study on March 23, 1988. Patients were ex- 
cluded from the study for the following reasons: history of 
sustained ventricular tachyxrhythmia or syncope: acole 
myacardizd infarction; sncompmx+ted congestive bear! faii- 
ore: severe renal. hepatic. hematologic. metabolic or pulmo- 
nary disease; amiodarone ,rea,ment within 6 months of 
screening and previous treatment wth or sensitivity to 
moricizine. AU other antiarrhythmic agents were discontin- 
ued 95 half-lives before screening. 
Protocol. Patient3 had baseline evalua,~on to determine 
drug-free signal-averaged ECG and standard ECG values 
during a I week predrug placebo period. A complete history. 
physical examination, chest X-ray film and blood chemistry 
values were obtained. In addition. two consecutive 24 h 
ambulatory ECG recordings were made. The average ven- 
tricular premature complex frequency over 48 h was calcu- 
lated as the predrug value. Treatment bepan with moricirine. 
200 mg orally eveiy 8 h. and the dose-was increased to a 
maximum of 300 me every 8 h if r80% suooression of 
ventricular prematu~ complexes did no, o&. Signal- 
averaged ECGs were evaluated for each patient who 
achieved n80% ventricular premature complex suppression 
on 200 to 300 mg of moricizine taken orally every 8 h l,he 
e5ective dose). or whose arrhythmia was no, uppressed by 
300 ntg of moricizine every 8 h (the maximal dose). All 
patients were studied during steady state therapy. 25 half- 
lives tier initiation of moricizine ,heraw. A, 0. I, 2.4.6 and
8 h after a morning dose. patients had s&l recordings of the 
signal-averaged and standard ECGs. and plasma was oh- 
tained for measuring maricizine concentration. Time tl was 
used to represent the time of moricizine administratton 
during steady state. Arrhythmia frequency was assessed 
with 24 h ambulatory KG recordings during the 8 h dosing 
interval. 
recordsd and analrred with the Predictor xys,em ICorazonix 
Corp., and revieued by one of the inveatigaalors. The tech- 
nique wed here has been deccrihed (231. Briefly. an orthot- 
nnal lead arrangement with bipolar X. Y and Z leads was 
wed. The QRS \ipnal was digitized a, a frequency of ?.uoO 
sample\:,. Templates were selected by ,he operaror and 
QRS complexes not matching rhe remplate ai,h a 99% 
corrcla,~on coeffic~en, were rejected. The QRS complex wab 
acquired in a none end point of 0.3 *V and a bidirecrional 
filter with a bandpar cutoff of40 to 250 Hz aa< applied. The 
QRS compiew of Be three bipolar leads were comb,.,ed 
into il vec:or magnitude by the formula U’X’ + Y- L Z’. An 
abnormal signal-averaged ECG was present if any of rhe 
Indexes IffIRS. V4O or LAS) were abnormal on the vec,or 
lead. Abno&al ralues WEW: fQRS >I10 I,,$. V40 <?O ,,V 
and LAS >38 mb. The signal-averaged ECG of 811 patients 
was awd for analysis of ven,ricular conduction. Pa,ien,s 
w&h bundle branch block were excluded only from signal- 
averaged ECG categorization into normal and abnormal 
groups before and during treatment. In the final analyrex 
signal-averaged KG variables were used to reprwn, vcn- 
uicuiar conducuon. 
Electroardiographic intervals. Standard KG recordings 
were made wsh a Marquette hlAC PC ECG Wxquerte 
Elec,romc*l tha, measures I2 leads simukancously. and PR. 
QRS and hear, rate-corrected QT (QTcl and JT (JTc) inter- 
vals were meawrcd manually by one of the mvertigators 
with handheld calipers. Standard ECG intervals were mca- 
wed in leads II and V2 or V, (24). Al least five measure- 
ments of each interval were made and ,he average was 
determmed. The QTc interval was calculaled with &e,,‘r 
formula: OTC = OTla The JTc interval was calculated 
in simdar&sh& In the final analyzer. the calculared JTc 
imerval was urcd to represent ventricular repolarization. 
Plasma drug concentration and pharmacokiiic analysis. 
Moricizine plasma concentration was determined by using a 
modification of a high performance liquid chromatography 
technique with ultraviole, detection. wavelength 268 nm (251 
at the Pharmacokinetics Section of Du Pant. Elimination 
half-life (t h) was calculated from the ,wminal portion of rhe 
log c’ .-enmtion-time plot: t H = 0.693ike. where ke is an 
elim. ..on ~a.2 constant. The trapezoidal rule was used IC 
~alc~la,e area under the plasma-drug time curve fAUCI. 
Twentyfour hour amhukxtwy ECC reeoti,np. Ambula- 
tory ECG recordings containing at least i8 h of analyzable 
data were made on 2 co,.%culive days during the baseline 
placebo period and the 8 h dosing interval. and rhe frequency 
of ventricular premature complcncslh was calculated. Re- 
cordmgs were obtained on Cardio Tech Corder I1 series 2 
channel recorders and analyzed by Cardio Cata Systems. 
Relation of morieiaine conceWation to sienal-averaeed 
Signal-averaged ECG intervals. Ueasurements of the LO- ECC and arrhythmia. Patients with 26 vent&dar prema- 
tal filtered QRS duration IfQRS). root-mean-square IRMS) tore complexesih during treatment were eligible for compar- 
voltage in the terminal 40 ms of the QRS 0’40) and ,he iron of signal-averaged ECG changer and ventricular prema- 
terminal low amplitude signal duration <40 WV (LAS) were ture complex frequency on the signal-averaging day. This a 
priori criterion was based on arrhythmia frequency required 
for CAST enrollment t I ). 
Statistical analysis. Data are expressed as mean values 2 
SD and median. Analysis of variance wus used to compare 
the signal-averaged KG and standard ECG variables over 
time. Post-hoc cumparisons between individual time points 
were made with Tukey’a test. A p value < 0.05 was 
considered statistically significant. 
Results 
Clinical characferistics (Table I). Sixteen patients were 
enrolled and had signal-averaged ECG and dererminatian of 
drug concentration over an 8 h dosing interval. Ten were 
taking one or more cardiac drugs: angiotensin-converting 
enzyme inhibitor In = 7). digitalis (n = 4). beta-adrenergic 
blocking agent fn = 2). calcium channel blocking agent (n = 
2). diuretic in = 2). nitrate (n = 21. antihvwtensive went 
(n = I). zambinatmn beta-blocker-antih;bertensive a&t 
(n = I). diuretic-antihypertensive agent (n = II and a 
potassium supplement (n = I). The mean moricizine dose 
was 213 t 29 mg every 8 h: I3 patients were taking 203 mg 
of mowiLme orally every 8 h. 2 were taking 250 mg and I 
was taking 300 mg. 
Signal-averaged ECG inferwls (Table 2). Of the 16 pa- 
tients enrolled. 6 met the criteria for an abnormal rignal- 
averaged ECG before taking moricizine: another 5 had 
bundle branch block and were not categorized into a normal 
or abnormal group and the remaining 5 were categorized as 
normal. Afler treatment. the signal-averaged KG of two 
patients converted from normal to abnormal. 
Comparison of the prcdrug and time II variables on the 
day of steady state measurements from the I6 patients 
showed that the mean total filtered QRS duration (fQRS) 
prolonged significantly :aom III i :I ms to 120 + 
26 ms (+ IO%, p < 0.05). while root-mean-square voltage of 
the terminal 40 ms of the QRS complex 0’40) decreased 
frum 34 ? 28 to 27 t I7 PV (-29%. p = NS). There was no 
difference in the terminal low amplitude signal duration 
(LAS): 41 2 26 ms predrug and 40 1 I7 at t&e 0. 
In the I6 patiems. over the 8 h dosing interval fQRS 
prolonged significantly (p < 0.05). V40 decreased signiii- 
cantly (p < 0.05) and there was no overall change in LAS 
(p = NS) (Table 2). Maximal fQRS prolongation from I20 r 
26 to 130 ? 28 ms (tB%, p < 0.05) occurred at 2 h and 
returned to time 0 values by 8 h. In 9 ofthe I6 patients fQRS 
increased by ~5%. V40 decreased over time with the largest 
decrease seen 2 h after drug administration from 27 t I7 pV 
at time 0 to I8 + II p (-33%. p < 0.05) at 2 h. LAS 
increased as did fQRS; however, the overall change war not 
significant: 40 + I7 at time 0 to 44 * I9 ms (+ 10%. p = NS) 
at 2 h. When plotted over time fQRS and LAS reached a 
peak value at 2 hand then declined at 8 h to values similar to 
those at time 0. Similarly. V40 decreased to the lowest value 
at 2 h and returned to vzdues similar to those at time 0. A 
representative patient’s lime 0 and 2 h signal-averaged ECGs 
(Fig. I) illustrate the changes in conduclion intervals that 
characterized moricizine treatment. 
To lest whether ejeclion fraction aJTenedfQRS change, 
patients were grouped into two categories: ejection fraction 
430% versus ejection fraction ~30%. There was no signift- 
Table 2. The Effect of Moricizine on the Signal-Averagrd ECG and the I2 Lead ECG in I6 Patients 
Swnty aat* tin 
Figure 1. A, Signal-averaged cle~troeardiopram re- 
corded at the lime of moricizine admimrtmtian 
during steady ~,a,e therapy, The tolrd filtered QRS 
duration (fQRS) WE I17 m. the m-mean-square 
volhge of the terminal 40 ms of the QRS complex 
WO) was 28 BV and the falal low amphludc &al 
duration ILASI was 35 ms. 8. Two hour, afwr the 
dose of moricizine. fQRS prolonged to 126 m,. 
LAS to 39 ms and “4” declined to IS r”. 
can, difference in fQRS change dependent an ejection fnc- 
tiOn; that is. the values were IO f I2 ms for those wi!h an 
ejeclion fraction <30% versus 7 5 8 ms for those wsh an 
ejeclion fraction a308. 
Standard ECG intervals (Table 2). In the 16 patients. 
significant prolongation of the PR interval and the QRS 
complex occurred from the predrug period to lime O.-al- 
though no change in the QTc or JTc intervals occurred. The 
PR interval Droloneed from I68 i 26 to I86 f 35 ms I+ I I%. 
p c 0.05). & did ie QRS interval. from 98 2 19 to 106 + 
23 ms (i8s. p < 0.051. The QTc mterval was 423 t 24 ms 
during the prcdrug period and 426 2 28 ms at time 0 Ip = NS) 
and the JTc inlerval was 315 2 23 ms during the prcdntg 
period and 312 ? 40 ms at time 0 (p = NS). 
Owl- rhr 8 I, dosinfi br~nwl r/w QRS nnd /he JTc 
bmrmds pmlnngrd si,&icnntly (p < 0.05). but the overall 
change seen in the PR and QTc intervals was of borderline 
Wficsnce (p = 0.09) (Table 2). The mean maximal change 
in ECG imervalr wx seen 2 h after mcricidne administm- 
lion. except for lhe QTc interval. which changed maximally 
at 4 h. The PR interval pmlonged from 186 + 35 at time 0 Lo 
198 2 37 m, at 2 h (+6%.), the QRS interval from 106 + 23 
to I IS 5 21 ms at 2 h (+8%. p < 0.05). the QTc interval from 
426 2 28 to 444 f 30 ms at 4 h (+4%) and the JTc interval 
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Figure 2. Relation between percent change m fQRS and moricinine 
concentration. The peak change in fQR.5 was measured at 2 h and 
pwk change in monctzme concentration was measured at I h after 
drug adminirtraion. The fQRS and drug concenlratiw curves 
decbne in parallel. supgcrting that the fQRS changer .rJect myo- 
cardial dmg concentration. 
from312 ? 40 to 324 t 43 msat 2 h ,+4%, p = 0.06). At the 
end of 8 h these standard ECG values declined to those 
obtained at time 0. 
iuoricizine plarma concentration. The time course of 
moricizine was monitored for 8 h after the morning dose. 
Mean moricizine plasma concentration was 0.1 f 0.1 &g/ml 
(range 50.1 to 0.3) at time 0 and reached a maximal 
concentration of 0.9 * 0.6 &ml (range 50. I to 2.1. p < 
0.05) at I h. Thereafter, the plasma concentKitiOtt (&g/ml) 
declined to 0.6 ? 0.5 (range ~0.1 to 2.0. p < 0.05) ilt 2 h, 
O.2~O.2,sO.ltoO.5)at4h,O.l~O.I,rO.lto0.3)at6h 
and 0.1 i 0.1 ($0.1 to 0.4) at 8 h ,Fie. 21. The terminal 
elimination half-life at steady state ~~-2.5 + 0.9 h (range 
1.6 to 4.2, median 2.3 h). The area under the plasma 
concentration-time curve was 2.3 ? I.3 pgh per ml. 
Relallon of signal-averaged and standard EC& to mori. 
cizioe plasma concentration. After drug absorption the two 
curves describing the changes in fQRS and the time course 
of plasma moricirine concentration were parallel (Fig. 2). 
suggesting that plasma drug concentration and myocardial 
effect are related. A similar relation was observed for 
rnoricizine concentration and LAS of the signal-averaged 
EC0 and also for the PR. QRS and 1Tc intervals of the 
standard ECG. 
R&l of moridzine on arrhythmia. Pretreatment venlric- 
ular premature complex frequency averaged 616 -c 624/h 
(range 76 to 1,907, median 386); the frequency decreased to 
52 2 77/h (range 0 to 236, median 14) (a decrease of 92%. 
p < 0.05) during moricizine treatment. Ventricular prema- 
ture complexes were suppressed ~80% in I5 of the I6 
patients. Ventricular tachycardia was present in I2 patients 
* 
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Figure 3. ReMan baween fQRS prolon~xion, plasma moricizine 
concentmlion and the frequency of ventricular premature corn- 
plexes WC) in seven patients with r6 ventricular premature 
complex&h after moricizinc administration. As ventricular prema- 
ture complex frqwney decreased. fQRS duration and morkizine 
concentration i creased. Thus. there was an inverse relation be- 
rween frequency 3f ventricular premature complexes versus tQRS 
prolongation and morieizine concentmtion after a dose. 
before treatment lmean number of episodes 14 + 102) and 
was abolished in IO patients after moricizine. Two others 
who had 39 and I56 predrug episodes of ventricular tachy- 
cardia had I and I5 episodes of ventricular tachycardia. 
respectively. on the day of study. 
7’0 assess the effect t$ moricizine on arrhvrhmia sutures- 
sion and rhe si&l-o&ged ECG in&Is, the &al- 
averaged ECG and ventricular premature compiex fre- 
quency were evaluated in seven patients who continued to 
have ~6 ventricular premature complex&. At time 0, the 
mean ventricular premature complex frequency was 284 f 
393/h and IQRS, V40 and LAS were I31 + 33 ms, 20 2 
I I PV and 43 t I5 ms, respectively. Maximal arrhythmia 
suppression and change in signal-averaged ECG variables 
occurred at 2 h, when mean suppression of ventrictdar 
premature complexes was 65 + 81/h and fQRS, V40 and 
LAS were I44 + 35 ms, I5 + 9 @V and 49 t 22 rns. 
respectively. Eight hours after moricidne administration 
both ventricular premature complex frequency and rignal- 
averaged ECG variables returned to time 0 values. Mori- 
cizine plasma concentration (&ml) was 0. I + 0.64 at time 0, 
1.0 t 0.9 at I h and 0.5 2 0.3 at 2 h. 
Discussion 
Eklrmwdivgmphic efkcts of moriciiitte. The present 
trial utilized the signal-averaged ECG to awess the effect of 
moricizine on cardiac conduction over a dosing interval. lo and QRS intervals: these findings are all consiaenr with the 
16 patiene wirh symptomalic ventricular premature com- present signal-averaged ECG results. 
plcxes, four major findings were observed. I) There were Prr, inw r~&s have indicated rhnt other un~iurrhyrhmir 
dynamic changes in the filtered QRS duration CfQRSl and ogen!s nlro uffrrf the ripwl-ovrmgud ECG indrres. Am% 
root-mean-square voltage of Ihe lcrminal 40 ms of the QRS darone at?.ctr all rignal-averaged ECG indexes and CBUMS 
comnlex @‘JO) on the sinnal-averwed ECG indicatinz &x- “late poicntial negative” patients wirh inducible ventricular 
ing if ventricular cond&ion: thewmaximal effect &m-red 
2 h after a dose. 21 There were changes in the JTc imerval of 
the standard ECG indicating mdd prolongation of ventricular 
repolarization; again, the maximal effects occurred at 2 h. 
3) The time course of moricizine plasma concentration 
paralleled the changes in the signal-averaged and standard 
EC&; the maximal effects occurred at I to 2 h. 4) In a 
subgroup of patients. the overall suppression of vemricular 
premawe complex frequency was most marked 2 h after 
drug adminlst%!icr! and then increased before a dose. The 
simultaneous delay in conduction and rcpokuization and the 
decrease in ventricular premature complex frequency sug- 
gest that these standard ECG changes may indicate mori- 
cizine’s mechanism of antiarrhythmic action. These effecr, 
on conduction and repolarization suggest that moricizine 
could be classified as a IA drug. having considerable e&t 
on conduction bui minimal to moderate effect on repolariza- 
lion (26). 
Effect of mnrieizine on venlricular conduction. Experi- 
mental mapping studies suggest that the signal-averaged 
ECG measnre~ the entire exwnt of ventricular activation. 
including retioos that have delayed onset of acrivatmn or 
slow conduction, or both (27). These “late” regions proba- 
bly indicate damaged ventricular tissue and. because of their 
slow conduction characteristics, are likely tu include polen- 
tial sites of reenuant circuits. Because these sites emit only 
small amplilude signals that do not register on the standard 
ECG, the processes of signal-averaging and signal amplifi- 
cation are required. Thus !he signal-averaged KG is capa- 
ble of monitoring conduction in all regions of ventricular 
myofardium. 
consistent with moricizine-induced slowing of conduction in 
the ventricular myocardium. The fQRS is a measure of total 
Significant dynamic changes were observed on the signal- 
averaged ECG (fQRS. V40) and standard ECG CQRS). 
tachycardia to become “late polenlial positive” (28). Simi- 
larly. Steinberg et al. (291 loo’lnd Ihal several type I drugs 
were assocmted with fQRS and low amplitude signal (LAS) 
prolongation. and with propafcnone. a type IC drug. LAS 
prolongation was responsible for the majority of fQRS 
change. In the present study, significant LAS prolongation 
was not observed. possibly because such prolongation is 
population specific: ihm is. it is more likely to be wen in 
patients with baseline late polentials. Connary toourexpec- 
rations. fQRS did not change out of proportmn to ihe QRS 
mterval. but rather to a similar degree. Only 5 of I I patients 
presented with late potentials. in contra1 10 an earlier study 
129) in which late potentials were present in 90% of patients. 
Another possible explanation is that LAS prolongation IS a 
drug-specific effect: that is. moricizine does not affect the 
kue potential in the manner of the type IC drug propafenone 
(29) or of amz&xone IX+). Compxiron of drugs with dif- 
ferem electrophysiologic characteristics in the same patients 
would be required to anwer this question. In ou. study. 
changes in atrioventricular conduction were of borderline 
significance over the dosing interval and paralleled the 
effects of moncizine on vemricular conduction. 
w. Signiiicant 
but mild dynamic JTc changes in the standard ECG were 
observed over time. Proloogation of the JTc interval snggests 
random times. rather than at systematic sampling intervals as 
mild drug-induced lengthening of venlricuhr r%dk.%ion. 
Previous studies (9.10.13.14) of moricizine describe little 
in our studv. could foil to detect minimal to moderate chaws. 
change or a decrease in ventricular repolarizalion. alriwgh 
increased ventricular refractorv oeriods have aIs0 been re- 
paled I 14). One possible e~p&&m for the differing resulls is 
that 5ome ~tudiis (10) utilizing the standard ECG did not 
correct the JT interval for hean rate. which increased during 
moricizine therapy: however. we did calculate JTc. Another 
exolaoation is that standard KG measurements made at 
ventricular activation; its prolongation indicated slowing of 
overall ventricular conduction in response 10 moricizine 
administration. The terminal portion of the fQRS (LAS) also 
changed, but less dramatically. The V40 is a measnrc of 
vobage in the terminal component of the QRS. A decrease in 
V40 induced by moricizine may indicate that a smaller mass 
of mvocardium deoalarized durinr the terminal seouence of 
Expaimen&l reports 110) usi@ isolated Purkinp fibeben i&e 
suggested that moricizbx decreases repolarization by shMen- 
ing phases 2 and 3 of the action potential. But these experi- 
mental results may differ from our present find@ because of 
the absence of any moricizirre melabolites. In addition. there 
may be profound diierences in drug elect depending on 
so&es. and labma.:~r~ models may not accumlel~ repre~n1 , 
acrivation. Less depolarized muscle mass may result from t/le myacardial effect; on human &es as rcccnlly empha- 
the crealion of conduction block, or simply from the prolon- sized by Wang et al. 03) forflecainide. Fmther studies in both 
galion of activation such that less muscle is acrivated per animal and clinical populations will be required to resolve this 
init of time. In laboratory models (I I), moricizine has been issue. 
shown to depress the maximal upstroke velocity of phase 0 Morieitine plasma concmbslh. Measurement of anti- 
depolarization in canine Purkiqje fibers. and clinical studies arrhy!hmic drug concentration has proved useful where a 
(9.13.14) reveal that moricizine significantly increases HV predictable concenlrarion effect exists. Animal studies 
(12.31) indicate that approximately I2 of40 metabolites have 
been identified after oral moricizine administration. but only 
I. moricizine sulfoxide. may have pharmacologic activity. 
Because moricizine is extensively metabolized. the relation 
between parent compound and dro? effect has not been well 
chamctcrized and efforts to test this relation are limited. In 
this trial. plasma moricizine concentration was measured at 
0. I, ?,4,6 and 8 h after drug administration. In accord with 
previous reports (12.31) indicating that the maximal concen- 
tration is reached within 0.8 to 2 h. moricizine levels peaked 
I to 2 h after a dose. The mean maximal changes on the 
signal-averaged and standard EC& occurred at 2 h. Thea- 
retically. it is possible that the maximal drug concentration 
and effect occurred simultaneously, at I to 2 h. This consid- 
eration, however, could not be tested because neither 
plasma samples nor srandard ECG variables were measured 
more frequently than at I and 2 h. 
Concordance between the parnllel time cowse of the 
parent compound and changes on the signal-averaged and 
standard ECGs suggest that moricizine alone or one or more 
rapidly formed metabolites. or both. could account for 
myocardial effects. It has been speculated that one or more 
active metabolite(s) contribute to moricizine’s sustained 
antiarhythmic action because doses given every 8 to I2 h 
are effective desdte the elimination half-life of 2 to 6 h (32). 
However, if lhe iherapeutic concentration range is wide and 
moricizinc concentration remains above the minimal effec- 
tive convzntration over a dosing interval, the major cardio- 
active effects crdd be accounted for by the parent com- 
pound despite a relatively short half-life. 
Moricizine effect on arrhythmia and the signal-averaged 
ECG. In the seven patients who had at least 6 ventricular 
premature complexes/h. not only did the maximal moricizine 
concentration and signal-averaged and standard ECG effects 
occur after I to 2 h, but also arrhythmia suppression was 
most marked. These observations suggest that moricirine- 
induced changes in conduction and repolarization may ac- 
count for maximal suppression of ventricular premature 
complexes. Thus, moricizine, like other drugs that prolong 
conduction and repolariation. could suppress ventricular 
premature complexes by further depressing conduction and 
prolonging refractoriness in a reentrant circuit. such that 
unidirectional block is converted to bidirectional blosk 
(15.33). Because moricizine also suppresses delayed after- 
depolarizations and triggered activity in Purkinje fibers and 
abnomml automaticity in depolarized Purkinje fibers (34). 
ttmtreentrant ventricular arrhythmias could be terminated as 
well. Further. the inverse relation between plasma concen- 
tration and arrhythmia frequency (Fig. 2) suggest that the 
parent compound could be responsible for the antiarrhyth- 
mic effect. Previous studies (12,321 implied that because of 
extensive metabolism, plasma concentration is not useful to 
monitor moricizine’s antiarrhvthmic effect: this may be true 
association between drug and arrhythmia suppression that 
will require further investigation. 
Conclusions. This trial utilized signal-averaged and stan- 
dard ECGs to estimate the myocardial effects of moricizine 
over a dosing interval. It was initiated with the premise that 
moricizine concentration is unreliable for estimating myo- 
cardial effect because of possible active metabolites. An 
unexpected finding was the parallel time course between 
plasma mor/cizine concentration and the conduction and 
repolarization changes. Because previous reports suggested 
extensive metabolism of moricizine and a poorly defined 
correlation between the parent drug concentration and an- 
tiarrhythmic eficacy. the relation between plasma concen- 
tration and intranodal and intraventricular conduction as 
well as repolarization changes is noteworthy. Future studies 
defining the electrophysiolagic properties of each of the > 12 
identifiable metabolites may help clarify whether metabolites 
also contribute to moricizine’s ECG and antiarrhythmic 
effects. 
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